Phosphonoformate en es it fr

Phosphonoformate Brand names, Phosphonoformate Analogs

Phosphonoformate Brand Names Mixture

  • No information avaliable

Phosphonoformate Chemical_Formula


Phosphonoformate RX_link

Phosphonoformate fda sheet

Phosphonoformate msds (material safety sheet)

Phosphonoformate MSDS

Phosphonoformate Synthesis Reference

Noren, Jan O.; et al., J.Med.Chem. 26(2) 264-270(1983)

Phosphonoformate Molecular Weight

126.005 g/mol

Phosphonoformate Melting Point

88.06 oC

Phosphonoformate H2O Solubility


Phosphonoformate State


Phosphonoformate LogP

No information avaliable

Phosphonoformate Dosage Forms


Phosphonoformate Indication

For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

Phosphonoformate Pharmacology

Foscarnet is an organic analogue of inorganic pyrophosphate that inhibits replication of herpes viruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Foscarnet does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to foscarnet. However, acyclovir or ganciclovir resistant mutants with alterations in the viral DNA polymerase may be resistant to foscarnet and may not respond to therapy with foscarnet. The combination of foscarnet and ganciclovir has been shown to have enhanced activity in vitro.

Phosphonoformate Absorption

Poorly absorbed after oral administration (bioavailability from 12 to 22%).

Phosphonoformate side effects and Toxicity

Oral, rat LD50: >2,000 mg/kg. Signs of overdose include renal impairment.

Phosphonoformate Patient Information

Phosphonoformate Organisms Affected

Human herpes viruses